Pricing Log in Create free account
Friday 6 November 2026 Export USNA’s income statement to Excel — free account

USANA Health Sciences, Inc.

USNA Consumer Defensive Packaged Foods

USANA Health Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $925.3 million, up 8.28% from fiscal 2024.

Revenue
−3.64%
EPS
−3.47%
Free cash flow
+180.6%

Quarter to September 2026, against a year earlier

13.58 0.28 −2.02%
Market cap
$256.1M
P/E
0.0×
Fwd P/E
−23.5×
Dividend yield
—
F-score
7/9
Altman Z
3.59
Beneish M
n/a
Dividend safety
70/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.89
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 — 1 2 — 4 4 — — — — —
Insider Ownership 40.97%

Capital & Financial Ratios $m

Size
Market Cap 256.09
Revenue ttm 905.58
Net income ttm (29.25)
Free cash flow ttm 19.90
Net debt Q (178.91)
Valuation
P/E 0.00
Forward P/E (23.50) (negative: loss-making)
Price / sales 0.28
Forward P/S Powerpack
Price / FCF 12.62
Price / book 0.48
Financial health
Current ratio Q 2.59 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (38.11)
Growth
Revenue growth Q −3.64% (below 0%: shrinking)
Operating income growth Q −218.30% (below 0%: shrinking)
EPS, this year −71.50% (below 0%: weak)
EPS, next year A +127.27% (at or above 15%: strong)
Revenue, next year A −1.76% (below 0%: weak)
EPS, past 5 yrs −37.03% (below 0%: weak)
EPS, next 5 yrs A −4.52% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 1.3×; over the ten years it ranged from 0.2× in 2026 to 2.6× in 2018.
P/S against its own 10 years 0.40%
10-year low 10-year high
P/B against its own 10 years 0.33%
10-year low 10-year high
EV/Sales against its own 10 years 0.07%
10-year low 10-year high
EV/FCF against its own 10 years 2.16%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 330 182 158 179
Receivables — — — 5
Inventory 61 70 103 84
Other — — — —
418 279 288 290
2023 2024 2025 Q'26
Payables 10 12 17 18
ST’ Debt — — — —
Other 108 105 97 95
119 140 129 112

Compound Annual Growth %

10y 5y 3y
Sales 0.07% (4.00%) (2.51%)
Cash Flow (14.84%) (32.58%) (40.08%)
Earnings (19.54%) (38.73%) (46.27%)
Book Value 6.62% 3.84% 7.06%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.11 Actual −0.11

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.41 0.60 Beat by 0.19
Q1 FY26 0.44 0.61 Beat by 0.17
Q2 FY26 0.43 −0.07 Miss by 0.50
Q3 FY26 0.11 −0.11 Miss by 0.22
Q4 FY26 0.11 — Reports 16 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.41 (1.16) (0.37) — —
’25 0.49 0.52 (0.36) (0.10) 0.58
’24 0.86 0.54 0.56 0.23 2.19
’23 0.95 0.89 0.59 0.87 3.30
’22 1.15 1.00 0.78 0.66 3.59
’21 1.45 1.87 1.36 1.03 5.73
’20 1.23 1.32 1.44 1.87 5.86
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 250 223 206 — —
’25 250 236 214 226 925
’24 228 213 200 214 855
’23 248 238 213 221 921
’22 273 264 233 228 999
’21 308 337 274 267 1,186
’20 267 259 299 311 1,135
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 10 23 — — —
’25 15 12 (2) (3) 22
’24 18 8 30 6 61
’23 13 10 22 26 71
’22 20 15 29 40 104
’21 20 39 37 25 121
’20 31 33 49 48 160
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 7 20 — — —
’25 13 7 (5) (2) 12
’24 14 5 27 4 51
’23 11 6 21 19 56
’22 18 13 26 37 94
’21 18 38 31 22 108
’20 24 29 46 46 145
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1,006 1,047 1,189 1,061 1,135 1,186 999 921 855 925 906 (0.9%) 909 945 — +1.1%
Gross margin, % 82.09 82.87 83.12 82.33 81.57 81.63 80.58 80.82 81.13 78.29 77.26 (3.8) pt
EBT 139 135 192 150 178 171 109 102 76 42 0 (12.5%)
EBT margin, % 13.77 12.86 16.10 14.19 15.68 14.38 10.88 11.12 8.94 4.49 (0.01) (9.3) pt
Net income 100 63 126 101 125 117 69 64 42 11 (29) (21.4%)
Per share, $
Per share, $ Revenue 41.60 43.01 49.34 46.85 53.63 58.89 51.86 47.84 44.73 49.92 48.96 +2.0%
Earnings 3.99 2.53 5.12 4.41 5.86 5.73 3.59 3.30 2.19 0.58 (1.22) (19.3%)
Cash flow 5.66 5.08 6.31 5.60 7.58 6.02 5.40 3.67 3.19 1.21 0.00 (15.8%)
Capex (1.35) (0.54) (0.46) (0.73) (0.71) (0.63) (0.54) (0.75) (0.52) (0.54) 0.00 (9.8%)
Free cash flow 4.31 4.54 5.85 4.87 6.87 5.38 4.86 2.92 2.67 0.67 0.00 (18.7%)
Book value 13.45 14.92 16.23 15.53 20.88 19.61 22.57 25.83 27.85 28.76 28.48 +8.8%
Shares, m 24 24 24 23 21 20 19 19 19 19 18 (2.9%)
Valuation, ×
Valuation, × P/E 16.13 29.74 23.04 17.77 13.16 17.72 15.17 16.50 16.31 35.69 0.00 20.1
P/S 1.50 1.74 2.39 1.68 1.44 1.72 1.05 1.14 0.80 0.39 0.28 1.4
P/B 4.62 5.02 7.26 5.06 3.69 5.16 2.41 2.11 1.29 0.68 0.48 3.7
EV/Sales 1.39 1.57 2.21 1.52 1.22 1.57 0.83 0.85 0.67 0.29 0.15 1.2
EV/FCF 13.38 14.87 18.62 14.61 9.53 17.19 8.84 13.96 11.18 21.84 6.95 14.4
Cash, $m
Cash, $m Operating cash flow 137 124 152 127 160 121 104 71 61 22 28 (18.2%)
Capex (33) (13) (11) (17) (15) (13) (10) (14) (10) (10) (8) (12.4%)
Free cash flow 104 111 141 110 145 108 94 56 51 12 20 (21.0%)
Balance, $m
Balance, $m Working capital 139 199 244 193 257 204 241 299 140 160 178 +1.5%
Net debt (176) (247) (278) (235) (312) (240) (288) (330) (182) (158) (179) (1.2%)
Shareholders’ equity 325 363 391 352 442 395 434 497 532 533 527 +5.6%
Returns, %
Returns, % ROA 22.38 12.63 23.51 18.77 21.53 19.12 11.81 10.38 6.09 1.44 (2.95) (20.9) pt
ROIC 57.95 71.34 103.92 78.17 85.03 68.50 46.05 34.88 11.83 6.24 (0.67) (51.7) pt
ROE 33.01 18.17 33.47 27.06 31.43 27.85 16.72 13.69 8.17 2.02 0.00 (31.0) pt
People
People Employees 1,788 1,810 1,911 1,909 1,943 1,978 1,900 1,800 1,700 1,570 — (1.4%)
Revenue/emp, $m 0.56 0.58 0.62 0.56 0.58 0.60 0.53 0.51 0.50 0.59 — +0.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

USANA Health Sciences, Inc. vs peers in Packaged Foods (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OFRM Once Upon a Farm, PBC $384.2M 9.8× — (loss-making) +68.75% (above 0%: growing) n/m +59.77% (above 0%: growing) 35.89% (6.60%) Compare
LWAY Lifeway Foods, Inc. $335.4M 30.0× 43.3× +24.10% (above 0%: growing) −96.43% (below 0%: shrinking) −598.84% (below 0%: shrinking) 19.47% 0.90% Compare
ENHA Enhanced Group Inc. $323.3M 11.0× — — n/m −483.42% (below 0%: shrinking) 100.00% (349.85%) Compare
PRE Prenetics Global Limited $273.0M — (loss-making) — (loss-making) +288.57% (above 0%: growing) n/m −297.16% (below 0%: shrinking) 64.97% (45.13%) Compare
USNA USANA Health Sciences, Inc. $256.1M — (loss-making) — (loss-making) −3.64% (below 0%: shrinking) n/m +180.61% (above 0%: growing) 76.34% (0.70%)
OTLY Oatly Group AB Sponsored ADR $245.7M — (loss-making) — (loss-making) +9.09% (above 0%: growing) n/m −254.68% (below 0%: shrinking) 34.14% (3.78%) Compare
BRCC BRC Inc. $244.5M — (loss-making) 42.0× +7.27% (above 0%: growing) n/m −141.35% (below 0%: shrinking) 37.14% (6.93%) Compare
BGS B&G Foods, Inc. $200.8M — (loss-making) — (loss-making) −9.70% (below 0%: shrinking) n/m +19.28% (above 0%: growing) 20.78% 9.02% Compare
NATR Nature's Sunshine Products, Inc. $180.5M 13.1× 11.5× −9.14% (below 0%: shrinking) −64.03% (below 0%: shrinking) −45.13% (below 0%: shrinking) 72.86% 4.53% Compare
Median of peers $259.4M 12.1× 42.0× +9.09% — −198.01% 36.52% (5.19%)

All 68 Packaged Foods stocks →

Pay and ownership Proxy statement filed 7 April 2026

Ownership

Directors and executive officers, together less than 1%
Gull Global, Ltd. PO Box N-4899, 40.10%
Renaissance Technologies LLC 6.20%
Pzena Investment Management LLC 6.10%
Vanguard Group Inc. PO BOX 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

USANA Health Sciences, Inc. (USNA) Latest News

4 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby

3 Nov

Impact 3 · · Zacks
Impact 3 · · StockStory
Impact 3 · · Associated Press
Impact 3 · · Business Wire

7 Oct

Impact 3 · · PR Newswire

30 Sep

Impact 3 · · StockStory

31 Aug

Impact 3 ·

12 Aug

Impact 3 ·

11 Aug

Impact 3 · · The Motley Fool transcript

9 Aug

Impact 4 · · MarketBeat transcript

6 Aug

Impact 4 ·

5 Aug

Impact 4 · transcript

4 Aug

Impact 4 ·
Impact 4 ·

14 Jul

Impact 3 ·

15 May

Impact 3 · · StockStory

8 May

Impact 4 · · Simply Wall St.

6 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby

5 May

Impact 4 · · StockStory
Impact 4 · · Business Wire
Impact 3 · · Zacks

4 May

Impact 3 · · StockStory

27 Apr

Impact 3 · · StockStory

16 Mar

Impact 3 · · Zacks

10 Mar

Impact 3 · · Zacks

2 Mar

Impact 4 · · StockStory
stockrow.com/USNA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com